SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered a collaboration with Oxford University in the United Kingdom to provide TPOXX® (tecovirimat) under an expanded access protocol to treat individuals affected by monkeypox in the Central African Republic (CAR). Under the agreement, Oxford University will sponsor the protocol and study in CAR, and SIGA will provide up to 500 courses of TPOXX (tecovirimat) at no cost.
Read more about this news here.
